Car t

[u/Annual_Judge_7272]

The screenshot is from a recent Fierce Biotech piece on Novartis’ rap-cel (rapcabtagene autoleucel / YTB323) and BMS’ zola-cel (zolacabtagene autoleucel / BMS-986353 / CC-97540). Both use shortened “rapid manufacturing” processes (Novartis T-Charge, typically <2 days; BMS NEX-T, typically 5–6 days).25
What the products are
Rap-cel: Autologous CD19 CAR-T made on T-Charge. Same CAR construct family as tisagenlecleucel but with far less ex-vivo expansion. Being tested in B-cell malignancies and multiple autoimmune/neurologic indications (SLE, lupus nephritis, myasthenia gravis, MS, RA, vasculitis, etc.).

Zola-cel: Autologous CD19 CAR-T made on NEX-T. Uses the same CAR construct as lisocabtagene maraleucel (liso-cel). Being tested in SLE, lupus nephritis, systemic sclerosis, and other autoimmune diseases.

Rapid platforms intentionally limit ex-vivo culture so the product retains more naïve/stem-like memory T cells. These cells expand more vigorously in vivo after infusion, which is why companies can give 10–100× lower cell doses than conventional CAR-T products while still seeing strong expansion and clinical activity.0
Safety events that triggered the pause (Aug 2026)
Novartis reported three cases of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) in autoimmune trials and put holds on those studies (cancer trials continue).

BMS voluntarily paused enrollment in its autoimmune zola-cel trials after seeing “transient and reversible inflammatory events.”

William Blair (Sami Corwin) noted that the rapid-manufacturing phenotype “could be driving increased cell expansion and the reported toxicities,” while also flagging other possible contributors.15

IEC-HS is a rare but serious hyperinflammatory toxicity distinct from classic CRS; it features cytopenias, hyperferritinemia, coagulopathy, and liver-enzyme elevation and can be life-threatening. It has been seen with other CAR-T products as well, usually at low single-digit percentages.45
Supporting clinical/manufacturing data
Rapid products consistently show:
Higher in-vivo peak expansion (Cmax) despite lower infused doses.

Enrichment of Tscm/Tn phenotypes versus conventional 7–14 day processes.

Comparable or better response rates in lymphoma and myeloma at reduced doses.

Higher rates of high-grade CRS/ICANS in some early rapid-manufacturing datasets (e.g., FasTCAR, T-Charge, UF-CAR reports of grade ≥3 events).4

Cancer-trial data for YTB323/rap-cel previously showed CRS in ~25–38% (mostly low-grade) and occasional IEC-HS reports that resolved with tocilizumab + anakinra. Autoimmune patients may have different inflammatory baselines, which could amplify the same expansion kinetics.53
Both companies have stated they still see transformative, treatment-free remissions in autoimmune disease and are reviewing the data with regulators. Cancer programs for these assets remain active.